These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9412400)

  • 1. [Efficacy and tolerance of coamoxiclav in community-acquired lower respiratory tract infections in children].
    Blokhin BM; Aldonina VV; Kozhukhova TM; Nikulin LA; Rumyantsev AG
    Antibiot Khimioter; 1997; 42(10):29-32. PubMed ID: 9412400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Coamoxiclav in the empirical monotherapy in outpatients with community acquired pneumonia].
    Yakovlev SV; Leshchenko IV; Kolesnikov VV; Suvorova MP
    Antibiot Khimioter; 1997; 42(10):19-22. PubMed ID: 9412398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
    Petitpretz P; Chidiac C; Soriano F; Garau J; Stevenson K; Rouffiac E;
    Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
    File TM; Jacobs MR; Poole MD; Wynne B;
    Int J Antimicrob Agents; 2002 Oct; 20(4):235-47. PubMed ID: 12385678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Amoxycillin/potassium clavulanate in inpatients with bronchopulmonary infections].
    Nonikov VE; Konstantinova TD; Lenkova NI; Minaev VI; Ritchik LA
    Antibiot Khimioter; 1997; 42(10):15-8. PubMed ID: 9412397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of coamoxiclav and other antibiotics against S pneumoniae and H influenae from paediatric cases of acute respiratory infections.
    Krishnan P; Rajendran P; Sambandan AP; Anitha C; Chavda RK; Khobragade KJ
    J Indian Med Assoc; 2011 Apr; 109(4):241-2, 244. PubMed ID: 22187795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Amoxicillin/clavulanic acid (875/125 mg). New pharmacodynamic aspects].
    Lode H
    Dtsch Med Wochenschr; 1999 Dec; 124(48):1459-61. PubMed ID: 10615328
    [No Abstract]   [Full Text] [Related]  

  • 9. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
    Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
    Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
    File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E;
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower respiratory tract infections in childhood. International Study Group.
    Klein M
    Pediatr Infect Dis J; 1995 Apr; 14(4 Suppl):S19-22. PubMed ID: 7792126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome.
    Hoepelman IM; Möllers MJ; van Schie MH; Greefhorst AP; Schlösser NJ; Sinninghe Damsté EJ; van de Moosdijk CN; Dalinghaus WH; Eland ME; Mol SJ; Rozenberg-Arska M
    Int J Antimicrob Agents; 1997 Jan; 9(3):141-6. PubMed ID: 9552709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms.
    Bantar C; Nicola F; Fernandez Canigia L; Arenoso HJ; Soutric J; Montoto M; Blanco M; Smayevsky J; Jasovich A
    J Chemother; 2001 Aug; 13(4):402-6. PubMed ID: 11589483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections.
    Balgos AA; Rodriguez-Gomez G; Nasnas R; Mahasur AA; Margono BP; Tinoco-Favila JC; Sansores-Martinez RH; Hassan M; Beppo O; Wongsa A; Cukier A; Vargas F
    Int J Clin Pract; 1999; 53(5):325-30. PubMed ID: 10695094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000].
    Melo-Cristino J; Fernandes ML; Serrano N;
    Acta Med Port; 2001; 14(5-6):459-68. PubMed ID: 11878155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Empirical antibacterial therapy of community acquired pneumonia in outpatients].
    Yakovlev SV; Suvorova MP
    Antibiot Khimioter; 1997; 42(10):23-8. PubMed ID: 9412399
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empirical treatment of influenza-associated pneumonia in primary care: a descriptive study of the antimicrobial susceptibility of lower respiratory tract bacteria (England, Wales and Northern Ireland, January 2007-March 2010).
    Blackburn RM; Henderson KL; Lillie M; Sheridan E; George RC; Deas AH; Johnson AP
    Thorax; 2011 May; 66(5):389-95. PubMed ID: 21357586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etiology and treatment of community-acquired pneumonia in ambulatory children.
    Wubbel L; Muniz L; Ahmed A; Trujillo M; Carubelli C; McCoig C; Abramo T; Leinonen M; McCracken GH
    Pediatr Infect Dis J; 1999 Feb; 18(2):98-104. PubMed ID: 10048679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.